Start Date
May 6, 2022
Primary Completion Date
August 1, 2022
Study Completion Date
August 1, 2022
nomacopan (rVA576)
Nomacopan an inhibitor of complement C5 and LTB4
Placebo
Placebo
UMPC Department of Dermatology, Pittsburgh
MENSINGDERMA Research GmbH, Hamburg
Universitätsklinikum Schleswig-Holstein, Kiel
Duke Dermatology, Durham
Wright State Physicians 725 University Blvd., Fairborn
Dawes Fretzin Clinical Research Group LLC, Indianapolis
David Fivenson MD PLC, Ann Arbor
North Shore University Health System, Skokie
Tulane University Health Sciences Center, Los Angeles
Universitäts Hautklinik, Tübingen
University Medical Center Groningen, Groningen
Cityclinic Przychodnia Lekarsko-Psychologiczna Matusiak Spółka Partnerska, Wroclaw
Lead Sponsor
AKARI Therapeutics
INDUSTRY